Bayer Presents New Data for Contrast Agent Gadoquatrane from Phase III Program at ECR 2026
New analyses show Bayer’s investigational MRI contrast agent delivers non-inferior diagnostic performance while reducing gadolinium dose by 60%.
Innovating Cancer Care: Bayer’s Low-Dose Contrast Enhanced MRI
Advancing radiology for smart imaging
Bayer files for EU approval of gadoquatrane
Submitted dose corresponds to 60% gadolinium reduction compared to standard macrocyclic agents
This website uses cookies to give our readers the best website experience. Please refer to our privacy policy to find out how we use cookies and how you can edit your preferences.
